View More
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA
Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com
In this commentary from Clinical Care Options (CCO), Alexander Drilon, MD, discusses best practices in the use of TRK inhibitor therapy
Alexander Drilon, MD
Released: July 10, 2020
From ASCO 2020, niraparib plus bevacizumab prolonged PFS and time to subsequent therapies over niraparib alone in recurrent ovarian cancer as reported by Clinical Care Options (CCO)
DESKTOP III results from ASCO 2020 show substantial survival benefit with complete resection in select patients with ovarian cancer as reported by Clinical Care Options (CCO)
Analyses of optimal niraparib dosing in ovarian cancer and in patients with moderate hepatic impairment from ASCO 2020, as reported by Clinical Care Options (CCO)
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.
CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.